ReviewBioMed research international2013
Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 53 citations in OpenAlex.
- Impact of simulation settings, time-activity curve integration range, and imaging time points on full Monte Carlo-basedAnnals of nuclear medicine · 2026Article
- Synthesis, preclinical evaluation, and clinical translation of [European journal of nuclear medicine and molecular imaging · 2026Article
- Altered biodistribution of [European journal of nuclear medicine and molecular imaging · 2024Article
- The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.Cancers · 2023Review
- Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review.Pharmaceutics · 2022Review
- SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications.Head and neck pathology · 2021Article
- Review
- The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors.Journal of cancer research and clinical oncology · 2021Article
- Article
- Residual titanium flakes as a novel material for retention and recovery of rare earth and relatively rare earth elements.Environmental science and pollution research international · 2020Article
- Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up.Archives of medical science : AMS · 2017Article
- Genetic engineered molecular imaging probes for applications in cell therapy: emphasis on MRI approach.American journal of nuclear medicine and molecular imaging · 2016Review
- Gastrointestinal cancers in the era of theranostics: Updates and future perspectives.World journal of gastroenterology · 2015Review
- Positron emission tomography image-guided drug delivery: current status and future perspectives.Molecular pharmaceutics · 2014Review
- Development of single vial kits for preparation of (68)Ga-labelled peptides for PET imaging of neuroendocrine tumours.Molecular imaging and biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) are tumors originated from neuroendocrine cells in the body. The localization and the detection of the extent of NETs are important for diagnosis and treatment, which should be individualized according to the tumor type, burden, and symptoms. Molecular imaging of NETs with high sensitivity and specificity is achieved by nuclear medicine method using single photon-emitting and positron-emitting radiopharmaceuticals. Somatostatin receptor imaging (SRI) using SPECT or PET as a whole-body imaging technique has become a crucial part of the management of NETs. The radiotherapy with somatostatin analogues labeled with therapeutic beta emitters, such as lutetium-177 or yttrium-90, has been proved to be an option of therapy for patients with unresectable and metastasized NETs. Molecular imaging can deliver an important message to improve the outcome for patients with NETs by earlier diagnosis, better choice of the therapeutic method, and evaluation of the therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.